Opinion|Videos|November 6, 2024
Nipocalimab and FcRn Inhibitors in Generalized Myasthenia Gravis
Key Takeaways
- Combination therapy in gMG is used for patients with severe symptoms or inadequate response to monotherapy, enhancing treatment efficacy.
- Targeted treatments have revolutionized the management of newly diagnosed gMG patients, enabling more personalized therapeutic strategies.
Panelists discuss how recent phase 3 trial results for nipocalimab and batoclimab, both neonatal Fc receptor (FcRn) inhibitors, demonstrate efficacy and safety in different generalized myasthenia gravis patient populations, comparing these findings with earlier phase 2 data and evaluating their potential impact on treatment approaches.
Advertisement
Video content above is prompted by the following:
- Phase 3 data of nipocalimab, an FcRn inhibitor, has recently been presented at the European Academy of Neurology and American Association of Neuromuscular and Electrodiagnostic Medicine conferences in 2024. Please review the efficacy and safety data for nipocalimab in different patient populations.
- What do phase 3 results add to phase 2 study findings with nipocalimab?
- What are your thoughts about nipocalimab data for generalized myasthenia gravis (gMG)?
- Please review the recently published data from the phase 3 trial of investigational FcRn inhibitor batoclimab for gMG.
Advertisement
Related to this article
In recognition of International Ataxia Awareness Day, observed annually on September 25, NeurologyLive® reviews 6 investigational agents in clinical development across ataxia-related disorders.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 25, 2026.
MS Compass: Guiding Clinical Care, a podcast hosted by neuroimmunologist Lindsay Ross, MD, brings you an exclusive interview with Rachel Galioto, PhD. [LISTEN TIME: 33 minutes]
A. Blake Buletko, MD, and Galina Gheihman, MD, discuss their career paths in neurology, the role of mentorship and resilience, and strategies for navigating professional growth as early-career clinician-educators.
One-year KYSA-6 data showed KYV-101, a CD19 CAR T-cell therapy, produced durable, drug-free responses in generalized myasthenia gravis.
Final 15-month phase 1/2 data showed SKY-0515 improved cUHDRS scores and lowered mutant huntingtin protein in early-stage Huntington disease.
The FDA has granted Scholar Rock's apitegromab fast track designation for the treatment of patients with living facioscapulohumeral muscular dystrophy as the company's phase 2 FORGE study dosing begins.
Tonic motor activation therapy was associated with reductions in RLS severity, along with tolerable reductions in dopamine agonist dosing, in adults with medication-refractory RLS.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
SKY-0515 Shows Sustained Benefit at 15 Months in Huntington Disease
2
Ulefnersen Meets Primary End Point in Phase 3 FUSION Trial for FUS-ALS
3
Closing the Gaps in Cluster Headache Care: Jennifer Fokas, MD; Minali Nigam, MD
4
From Biomarkers to Prevention: Key Alzheimer Research Stories of 2026
5